logo-loader
viewArca Biopharma Inc

Arca Biopharma progresses toward FDA approval of Gencaro as it beats 1Q expectations

Gencaro, a beta blocker designed to treat irregular heartbeat, received a Special Protocol Assessment from the Food and Drug Administration

Heart and stethoscope
The biopharmaceutical company reported a net loss of $1.86 per share, compared to a $3.61 loss in the prior year quarter

Arca biopharma Inc (NASDAQ:ABIO) posted a smaller-than-expected first-quarter loss as its lead drug progressed toward regulatory approval, the company announced Wednesday.

The biopharmaceutical company reported a net loss of $1.86 per share, compared to a $3.61 loss in the prior year quarter. That beat Street expectations of a $1.98 loss.

Cash and its equivalents increased to $8 million from $6.6 million last quarter.

READ: Arca Biopharma rockets after ‘encouraging’ data for beta-blocker Gencaro

Gencaro, its beta blocker designed to treat irregular heartbeat, received a Special Protocol Assessment from the Food and Drug Administration in February. That means its planned 2019 Phase 3 trial will be acceptable to secure FDA approval.

The Colorado-based company also plans to begin non-clinical studies later this year of AB171, a genetically-targeted treatment for heart failure and peripheral arterial disease.

After jumping 10% at the open, the stock fell back to earth, dropping 0.5% to $15.03.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Arca Biopharma Inc

Price: 12.68 USD

NYSE:ABIO
Market: NYSE
Market Cap: $20.21 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

2 hours, 32 minutes ago

2 min read